[8-K] FibroGen, Inc Reports Material Event

Rhea-AI Filing Summary

FibroGen, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025; the press release is included as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.

The company states the press release is furnished (not deemed "filed") for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other SEC filings. This 8-K does not include numerical financial results within the filing text; investors should review Exhibit 99.1 for the detailed figures and disclosures.

Insights

Securities Analyst

TL;DR: Routine earnings press release furnished; filing contains no financial figures itself.

This 8-K notifies the market that FibroGen furnished a press release with quarterly results for the period ended June 30, 2025, and attaches Exhibit 99.1 and an Inline XBRL cover page. The filing is procedural: it makes the market aware the company released results but does not present the numbers in the 8-K body. From an analyst perspective, the filing is neutral in impact until the content of Exhibit 99.1 is reviewed for revenue, earnings, cash flow or guidance changes.

Corporate Governance Specialist

TL;DR: Disclosure follows standard practice; the company clarifies legal treatment of the press release.

The company explicitly states the press release is "furnished" and not "filed," limiting Section 18 liability and excluding automatic incorporation by reference into other filings. That legal clarification is standard for press releases attached to Form 8-K. The filing provides transparency about where detailed information appears (Exhibit 99.1 and Inline XBRL Exhibit 104) but does not itself change corporate governance or control structures.

0000921299false00009212992025-08-112025-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

FIBROGEN, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-36740	77-0357827
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
350 Bay Street Suite 100 #6009
San Francisco, California				94133
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 415 978-1200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		FGEN		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02, in Exhibit 99.1 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by FibroGen, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)	Exhibits
Exhibit No.			Description
99.1			Press Release dated August 11, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			FIBROGEN, INC.
Date:	August 11, 2025	By:	/s/ David DeLucia
			David DeLucia Senior Vice President and Chief Financial Officer

FAQ

What did FibroGen (FGEN) report in this Form 8-K?

The 8-K states that FibroGen furnished a press release announcing financial results for the quarter ended June 30, 2025, provided as Exhibit 99.1.

Where can I find the detailed financial results referenced in the 8-K?

Detailed results are available in Exhibit 99.1 (the press release) and the filing also includes an Inline XBRL cover page as Exhibit 104 for interactive data.

Is the press release in the 8-K considered "filed" with the SEC?

No. The company states the press release is furnished, not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to certain filing liabilities.

Does this 8-K include the company’s financial statements or numerical results?

The body of the 8-K does not include numerical financial results; it furnishes a press release as Exhibit 99.1 where the detailed figures and disclosures appear.

Who signed the Form 8-K on behalf of FibroGen?

The Form 8-K is signed on behalf of FibroGen by David DeLucia, Senior Vice President and Chief Financial Officer.